Irish active-ingredient manufacturer Dunbar Pharmaceuticals has launched the UK’s first plant-derived dronabinol oral spray, extending a pharma-grade THC line that reached specialist prescribers in ...

Germany’s coalition government has retreated further on its controversial medical cannabis reimbursement reforms as it faces mounting questions over how and why the law came to be. A swathe of ...

Thousands of Dutch patients are facing a 10-month supply gap for medically essential Bedrocan products, including varieties clinicians consider irreplaceable for children with treatment-resistant ...

Bedrocan, the Dutch medical cannabis stalwart thousands of patients rely on for their prescriptions, is now fighting to avoid collapse. This week, Bedrocan’s two Dutch entities, Bedrocan Nederland B.V ...

James Duckenfield, CEO of Glass Pharms ®, dives into the responsibilities behind a medical cannabis brand and why pharmaceutical standards should matter more than marketing. From cultivation controls ...

Is cannabis legal in Spain? No, not on paper, and in practice it remains a grey area. Private possession and consumption fall outside Spain’s Penal Code through a judicial interpretation gap, not ...

Dr Nickel Dittrich is Managing Director of GMPion, a Berlin-based EU-GMP consultancy. Before founding GMPion, he spent more than five years at Cantourage, where he led the EU-GMP audit process for ...

A Michigan breach-of-contract dispute between cultivator Hello Farms and Curaleaf Holdings has cracked open a fault line that runs beneath every cannabis contract in the US, opening the door to a ...

James Duckenfield, CEO of Glass Pharms®, explains why we may be underestimating the pharmaceutical potential of cannabis, and how research, formulation… ...

PGP Farmer, the French biotech building the country’s first EU-GMP medical cannabis production site, has narrowed a 30-variety Dutch phenotyping trial to five elite cultivars, laying the agronomic ...

Government-led scientific studies from across Europe’s most progressive cannabis markets are solidifying an evidence base suggesting that greater access does not cause greater harm to public health.

The highly anticipated Advisory Council on the Misuse of Drugs (ACMD) review into the UK’s medical cannabis framework has, for the first time, received a new target publication date. In an update to ...